Adaptimmune Therapeutics PLC (ADAPY) KPIs and segments
Close on Oct 19, 2026Market cap $55.46MP/E –Yield –
KPIs & segments
Operating metrics and segments that drive Adaptimmune Therapeutics's business
Adaptimmune Therapeutics's revenue by segment, product and region, plus the counts and sizes it tags in its 10-K and 10-Q filings (XBRL). Each figure links to the filing it came from. A fuller KPI sheet built from earnings releases and presentations is on the way. See the segment tables for a trailing-twelve-month view, or how companies compare on operating metrics.
The chart is empty. Tick the box next to any metric in the table below to plot it — tick several to compare them on one chart.
Adaptimmune Therapeutics's fiscal year ends December 31 — Q2 2025 = CQ2 2025 (calendar quarter).
| Add to chart | Metric | Q2 2025 CQ2 2025 | Q1 2025 CQ1 2025 | Q4 2024 CQ4 2024 | Q3 2024 CQ3 2024 | Q2 2024 CQ2 2024 | Q1 2024 CQ1 2024 | Q4 2023 CQ4 2023 | Q3 2023 CQ3 2023 | Q2 2023 CQ2 2023 | Q1 2023 CQ1 2023 | Q4 2022 CQ4 2022 | Q3 2022 CQ3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Product revenue, net($M) | 11.1 | 4.05 | |||||||||||
Development revenue($M) | 2.60 | 3.24 | 1.99 | 40.9 | 128 | 5.68 | 0.23 | 7.32 | 5.13 | 47.6 | 11.0 | 7.01 | |
Commercial Sales($M) | 0 | ||||||||||||
Remaining performance obligations (RPO)($M) | 121 | 122 | 128 | 154 | 306 | 305 | 318 | 283 | 327 | ||||
1 metric has no data in the last 12 quarters — .
Italic numbers are calculated by StockData from reported figures (hover for the formula). Numbers with a dotted underline are read from the text of earnings releases and presentations; hover to see the exact sentence. Tick a row to add it to the chart above (up to 8 lines).
Methodology and excluded metrics
- Core rows come from the segment and revenue-disaggregation notes of 10-K and 10-Q filings (XBRL), linked to each filing. Fourth-quarter figures are the fiscal year less the first nine months (shown in italic).
Data updated 2025-08-13.
See a number that looks wrong?